drugset
drugset / Trial / NCT01546051

A Study of BCI-838 and Several BCI-632 Prodrugs in Healthy Volunteers

NCT01546051 ↗

Phase 1 Completed 31 enrolled BrainCells Inc.
RandomizedSingle-groupDouble-blindTreatment

Summary

This study will evaluate the safety, tolerability and pharmacokinetics of BCI-838, its metabolite BCI-632 and several new pro-drugs in healthy male subjects.

Timeline

Start
2011-10
Primary completion
2012-01
Completion
2012-02

Drugs

EvaluationDrugModalityDoseRoute
Subject BCI-1038 Unknown 1 mg Oral
Subject BCI-1206 Unknown 1 mg Oral
Subject BCI-1283 Unknown 1 mg Oral
Subject MGS-0210 Small molecule 30 mg Oral
Subject MGS-0210 Small molecule 100 mg Oral
Subject MGS-0210 Small molecule 300 mg Oral
Subject MGS-0210 Small molecule 900 mg Oral

Indications

No indication recorded.